Phase 1 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with a specific type of B-cell non-Hodgkin lymphoma (a blood cancer affecting B-cells) that has come back or stopped responding to treatment, and where no other more suitable approved treatments are available according to the treating doctor
- People with one of several specific subtypes of large B-cell lymphoma, as confirmed by a tissue sample analysis (a full list of qualifying subtypes would be confirmed by the trial site)
- People who have already received at least 2 previous lines of cancer treatment, including a treatment combination containing an anti-CD20 antibody (a type of targeted therapy)
- People who have had at least one prior treatment but are not suitable for, or cannot access, standard second-line treatments such as CAR-T cell therapy
- People whose cancer can be measured on scans according to standard criteria (called Lugano criteria)
- People with a general health and activity level rated at 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity)
- People of childbearing potential who have a negative pregnancy test at the start of the study and agree to further pregnancy tests during the trial
- All participants must agree to not breastfeed, not become pregnant, not donate or freeze eggs or sperm, and to use an external condom during treatment and for 3 months after the last dose
Who may not be able to join:
- People whose lymphoma has spread to the brain or the fluid surrounding the brain and spinal cord
- People who have previously had a solid organ transplant (such as a kidney, liver, or heart transplant)
- People who have been diagnosed with another cancer within the past year, except for certain skin cancers, cervical changes that have not become invasive cancer, or cancers considered fully cured with very low chance of returning (confirm with trial site)
- People who have an autoimmune or inflammatory condition that has required steroid tablets or other immune-suppressing medications within the past 3 months
- People who still have significant side effects from previous cancer treatments that have not returned to normal or near-normal levels (with some exceptions, such as hair loss, skin colour changes, certain nerve-related issues, or stable hormone-related conditions)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Phone: 844-434-4210
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Part 1 and 2: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) by Severity for JNJ-95566692 (Arm A) And in Combination With JNJ-87801493 (Arm B); Part 1: Number of Participants with Dose Limiting Toxicity (DLTs) for JNJ-95566692 (Arm A) And in Combination With JNJ-87801493 (Arm B)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.